253 related articles for article (PubMed ID: 25301112)
1. ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate.
Ali MA; Elsalakawy WA
Med Oncol; 2014 Nov; 31(11):279. PubMed ID: 25301112
[TBL] [Abstract][Full Text] [Related]
2. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
[TBL] [Abstract][Full Text] [Related]
3. SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.
Singh O; Chan JY; Lin K; Heng CC; Chowbay B
PLoS One; 2012; 7(12):e51771. PubMed ID: 23272163
[TBL] [Abstract][Full Text] [Related]
4. Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia.
Ben Hassine I; Gharbi H; Soltani I; Ben Hadj Othman H; Farrah A; Amouri H; Teber M; Ghedira H; Ben Youssef Y; Safra I; Abbes S; Menif S
Cancer Chemother Pharmacol; 2017 Oct; 80(4):829-839. PubMed ID: 28836054
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia.
Vine J; Cohen SB; Ruchlemer R; Goldschmidt N; Levin M; Libster D; Gural A; Gatt ME; Lavie D; Ben-Yehuda D; Rund D
Leuk Lymphoma; 2014 Nov; 55(11):2525-31. PubMed ID: 24524306
[TBL] [Abstract][Full Text] [Related]
6. Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.
de Lima LT; Vivona D; Bueno CT; Hirata RD; Hirata MH; Luchessi AD; de Castro FA; de Lourdes F Chauffaille M; Zanichelli MA; Chiattone CS; Hungria VT; Guerra-Shinohara EM
Med Oncol; 2014 Mar; 31(3):851. PubMed ID: 24469953
[TBL] [Abstract][Full Text] [Related]
7. ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib.
Vivona D; Bueno CT; Lima LT; Hirata RD; Hirata MH; Luchessi AD; Zanichelli MA; Chiattone CS; Guerra-Shinohara EM
Blood Cells Mol Dis; 2012 Feb; 48(2):132-6. PubMed ID: 22134106
[TBL] [Abstract][Full Text] [Related]
8. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.
Dulucq S; Bouchet S; Turcq B; Lippert E; Etienne G; Reiffers J; Molimard M; Krajinovic M; Mahon FX
Blood; 2008 Sep; 112(5):2024-7. PubMed ID: 18524988
[TBL] [Abstract][Full Text] [Related]
9. Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
Bedewy AM; El-Maghraby SM
Hematology; 2013 Jul; 18(4):211-6. PubMed ID: 23394475
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact of ABCC1 and ABCC2 genotypes and haplotypes in mediating imatinib resistance among chronic myeloid leukaemia patients.
Au A; Baba AA; Azlan H; Norsa'adah B; Ankathil R
J Clin Pharm Ther; 2014 Dec; 39(6):685-90. PubMed ID: 25060527
[TBL] [Abstract][Full Text] [Related]
11. MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis.
Zu B; Li Y; Wang X; He D; Huang Z; Feng W
Pharmacogenomics; 2014 Apr; 15(5):667-77. PubMed ID: 24798723
[TBL] [Abstract][Full Text] [Related]
12. Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients.
Elghannam DM; Ibrahim L; Ebrahim MA; Azmy E; Hakem H
Hematology; 2014 Apr; 19(3):123-8. PubMed ID: 23683876
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
Kim DH; Sriharsha L; Xu W; Kamel-Reid S; Liu X; Siminovitch K; Messner HA; Lipton JH
Clin Cancer Res; 2009 Jul; 15(14):4750-8. PubMed ID: 19584153
[TBL] [Abstract][Full Text] [Related]
14. Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis.
Jiang ZP; Zhao XL; Takahashi N; Angelini S; Dubashi B; Sun L; Xu P
Pharmacogenomics; 2017 Jan; 18(1):35-56. PubMed ID: 27991849
[TBL] [Abstract][Full Text] [Related]
15. Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib.
Gromicho M; Magalhães M; Torres F; Dinis J; Fernandes AR; Rendeiro P; Tavares P; Laires A; Rueff J; Sebastião Rodrigues A
Oncol Rep; 2013 Feb; 29(2):741-50. PubMed ID: 23229016
[TBL] [Abstract][Full Text] [Related]
16. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia.
Ni LN; Li JY; Miao KR; Qiao C; Zhang SJ; Qiu HR; Qian SX
Med Oncol; 2011 Mar; 28(1):265-9. PubMed ID: 20204543
[TBL] [Abstract][Full Text] [Related]
17. Impact of ABCB1 Gene Polymorphisms and Smoking on the Susceptibility Risk of Chronic Myeloid Leukemia and Cytogenetic Response.
Mohammadi F; Shafiei M; Assad D; Rostami G; Hamid M; Foroughmand AM
Iran Biomed J; 2021 Jan; 25(1):54-61. PubMed ID: 33129240
[TBL] [Abstract][Full Text] [Related]
18. Association between C1236T Genetic Variant of ABCB1 Gene and Molecular Response to Imatinib in Indonesian Chronic Myeloid Patients.
Rinaldi I; Nova R; Widyastuti R; Priambodo R; Instiaty I; Louisa M
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3331-3334. PubMed ID: 31759356
[TBL] [Abstract][Full Text] [Related]
19. Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.
Seong SJ; Lim M; Sohn SK; Moon JH; Oh SJ; Kim BS; Ryoo HM; Chung JS; Joo YD; Bang SM; Jung CW; Kim DH; Park SY; Yoon SS; Kim I; Lee HG; Won JH; Min YH; Cheong JW; Park JS; Eom KS; Hyun MS; Kim MK; Kim H; Park MR; Park J; Kim CS; Kim HJ; Kim YK; Park EK; Zang DY; Jo DY; Lee HW; Yoon YR
Ann Oncol; 2013 Mar; 24(3):756-60. PubMed ID: 23117072
[TBL] [Abstract][Full Text] [Related]
20. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]